CERO (CERo Therapeutics Holdings) Inventories, Inventories Adjustments: $ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Inventories, Inventories Adjustments?

CERo Therapeutics Holdings CERO +13.21% Inventories, Inventories Adjustments is $ Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

CERo Therapeutics Holdings's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2026 was $ Mil.

CERo Therapeutics Holdings Inventories, Inventories Adjustments Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Inventories, Inventories Adjustments Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Inventories Adjustments
- - - - -

CERo Therapeutics Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CERo Therapeutics Holdings Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

What does a Inventories, Inventories Adjustments of $ Mil mean?
CERo Therapeutics Holdings (CERO) has a Inventories, Inventories Adjustments of $ Mil as of Jun. 2026. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on CERo Therapeutics Holdings and its competitors.
Is CERo Therapeutics Holdings' Inventories, Inventories Adjustments too high?
CERo Therapeutics Holdings' current Inventories, Inventories Adjustments is $ Mil.
How does CERo Therapeutics Holdings' Inventories, Inventories Adjustments compare to AGTX and ZVSA?
CERo Therapeutics Holdings' Inventories, Inventories Adjustments of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Inventories Adjustments for a Biotechnology company?
A good Inventories, Inventories Adjustments depends on the Biotechnology industry context. However, Inventories, Inventories Adjustments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Inventories Adjustments mean?
A high Inventories, Inventories Adjustments can signal that a stock is expensive relative to its fundamentals. Inventories, Inventories Adjustments is certain charges made in the current period in inventory resulting from breakage, spoilage, etc. View historical data on CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current Inventories, Inventories Adjustments is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Inventories, Inventories Adjustments of $ Mil. The current Inventories, Inventories Adjustments is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Inventories Adjustments calculated?
Inventories, Inventories Adjustments is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Inventories, Inventories Adjustments is $ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc. is a clinical-stage immunotherapy company based in the United States that develops engineered T cell therapies for cancer. Its proprietary T cell engineering platform aims to combine features of innate and adaptive immunity into a single therapeutic construct, seeking to engage the immune system more broadly against tumors. The company's lead candidate is CER-1236, an autologous T cell product targeting TIM-4 ligand, a novel tumor antigen. CERo is focused on advancing this program through preclinical and early clinical development, initially in hematologic malignancies and potentially in solid tumors. As a development-stage company, it does not yet generate product revenue; its operations are funded primarily through equity financings and capital markets activity. Its activities are concentrated in the United States, where it conducts research and development.